
New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …

Amicus Therapeutics and Biogen Idec have signed a collaboration agreement which will see them look for novel small molecules for …

GlaxoSmithKline is to increase ownership in Amicus Therapeutics as the firms extend their collaboration to find a new drug for …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

